CNTX-4975
Stevens R, Guedes K, Armas E, Smith V, Volosov A, Campbell J. Evaluation of the Efficacy of Intra-articular CNTX-4975 in Subjects With Knee Osteoarthritis: Results From an 8-Week Study [abstract]. Presented at: PAINWeek 2019, Las Vegas, Nevada, September 3-7, 2019.
PAINWeek 2019
CNTX-4975
Stevens RM, Guedes K, Mistry N, Tiseo P, Lascelles D, Campbell J, Mendoza M, Ball D. Efficacy of Bilateral Intra-articular CNTX-4975 Injection for Management of Painful Knee Osteoarthritis. https://www.fsipp-conference.com/pdf/FSIPP%202019%20Educational%20Guide.pdf
The Florida Society of Interventional Pain Physician (FSIPP)
CNTX-4975
Stevens RM, Guedes K, Mistry N, Tiseo P, Lascelles D, Campbell J, Mendoza M, Ball D. Assessment of cooling methods for reducing procedural pain associated with CNTX-4975 injection for management of painful knee osteoarthritis. https://www.fsipp-conference.com/pdf/FSIPP%202019%20Educational%20Guide.pdf
The Florida Society of Interventional Pain Physician (FSIPP)
CNTX-4975
Stevens R, Guedes K, Mistry N, Lascelles D, Ball D. Intra-articular CNTX-4975 for painful knee osteoarthritis: assessment of cooling methods for reducing procedural pain. Ann Rheum Dis. 2019;78(suppl 2). http://dx.doi.org/10.1136/annrheumdis-2019-eular.1156
European League Against Rheumatism (EULAR)
CNTX-4975
Stevens R, Guedes K, Armas E, Smith V, Volosov A. Pharmacokinetics (PK) of a single intra-articular (IA) injection of CNTX-4975 (trans-capsaicin) vs topical 8% capsaicin patch. Ann Rheum Dis. 2019;78(suppl 2). http://dx.doi.org/10.1136/annrheumdis-2019-eular.5941
European League Against Rheumatism (EULAR)
CNTX-4975
Campbell J, Stevens RM, Hanson PD. Characterization of the pharmacology and pharmacokinetics of CNTX-4975, a high-purity, synthetic trans-capsaicin in clinical development for the treatment of moderate to severe OA knee pain [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/characterization-of-the-pharmacology-and-pharmacokinetics-of-cntx-4975-a-high-purity-synthetic-trans-capsaicin-in-clinical-development-for-the-treatment-of-moderate-to-severe-oa-knee-pain/
American College of Rheumatology (ACR)
CNTX-4975
Stevens R, Petersen D, Ervin J, Nezzer J, Nieves Y, Campbell J, Guedes K, Burges R, Hanson P. Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study. http://ard.bmj.com/content/76/Suppl_2/121.2
European League Against Rheumatism (EULAR)
CNTX-4975
Stevens R, Petersen D, Ervin J, Nezzer J, Nieves Y, Campbell J, Guedes K, Burges R, Hanson P. Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: a 24-week, randomized, double-blind, placebo-controlled, dose-ranging study. http://www.tandfonline.com/doi/abs/10.1080/00325481.2017.1367065
PAINWeek
CNTX-4975
Stevens R, Petersen D, Ervin J, Nezzer J, Nieves Y, Campbell J, Guedes K, Burges R, Hanson P. Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). http://acrabstracts.org/abstract/efficacy-and-safety-of-cntx-4975-in-subjects-with-moderate-to-severe-osteoarthritis-knee-pain-24-week-randomized-double-blind-placebo-controlled-dose-ranging-study/
American College of Rheumatology (ACR)
CNTX-6970
Stevens R, Silverman M, Mistry N, Biernat L, Guedes K. Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of the Selective Oral CCR2 Antagonist CNTX-6970 in Healthy Subjects [abstract]. Presented at: PAINWeek 2019, Las Vegas, Nevada, September 3-7, 2019.
PAINWeek 2019
CNTX-6970
Stevens R, Simons G, Brand T, Hetterna W, Corradini L. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of the Novel Oral CCR2 Antagonist, CNTX-6970, in Healthy Volunteers [abstract]. Presented at: PAINWeek 2019, Las Vegas, Nevada, September 3-7, 2019.
PAINWeek 2019
CNTX-6970
Stevens R, Scheuerer S, Schuelert N, Corradini L. Evaluation of the Selective Oral CCR2 Antagonist CNTX-6970 in the Treatment of Osteoarthritis Pain; Results from Preclinical Studies of Pharmacokinetics and Efficacy [abstract]. Presented at: PAINWeek 2019, Las Vegas, Nevada, September 3-7, 2019.
PAINWeek 2019
CNTX-6970
Stevens R, Simons G, Brand T, Hettema W, Corradini L, Pollenter S. Phase 1 study of the safety and tolerability of single ascending doses of the novel oral CCR2 antagonist CNTX-6970 in healthy volunteers [abstract]. Pain Med. 2018;19(4). doi.org/10.1093/pm/pny044 Published by Oxford University Press on behalf of the American Academy of Pain Medicine. Please visit: https://academic.oup.com/painmedicine/article/19/4/818/4954176
American Academy of Pain Medicine (AAPM)
CNTX-6016
Stevens R, Nicholson J, Sauer A, Nolter T, Corradini L. Evaluation of the Selective Oral CB2 Agonist CNTX-6016 for the Treatment of Neuropathic Pain: Pharmacokinetic, Efficacy, and Safety Findings from Preclinical Studies [abstract]. Presented at: PAINWeek 2019, Las Vegas, Nevada, September 3-7, 2019.
PAINWeek 2019
CNTX-0290
Stevens R, Corradini L, Doods H. Preclinical Evaluation of Human Somatostatin Receptor 4 (hSSTR4) Agonist CNTX-0290 for Mixed Pain Conditions [poster]. Presented at: American Pain Society, Milwaukee, WI, April 3-6, 2019.
American Pain Society (APS)
CNTX-0290
Stevens R, Guedes K, Kerns W, Fong K, Silverman M.H, Zhou G, Vrishabhendra L. Safety and Pharmacokinetics of Single Ascending Doses of Human Somatostatin Receptor 4 (hSSTR4) Agonist CNTX-0290 in Healthy Subjects [poster]. Presented at: International Congress on Neuropathic Pain, London, UK, May 9-11, 2019
International Congress on Neuropathic Pain (NeuPSIG)